Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Pancreatic Neoplasms 1Liver Neoplasms 1Hepatitis B 1Diarrhea 1Colorectal Neoplasms 1

Interventions

entecavir 9Tenofovir 3Lamivudine 3lenvatinib 2Sorafenib 2Hepatitis B Vaccines 2tenofovir alafenamide 1polysaccharide MGN3 1peginterferon alfa-2b 1navitoclax 1menatetrenone 1lens intermediate filament proteins 1human papillomavirus vaccine, L1 type 16, 18 1adefovir 1Ultrasonography 1Tumor Necrosis Factor-alpha 1Tetanus Toxoid 1Telbivudine 1Standard of Care 1Rapid Diagnostic Tests 1Raltegravir Potassium 1Radiofrequency Ablation 1Practice Guidelines as Topic 1Polymorphism, Genetic 1Pneumococcal Vaccines 1PHY 906 1Nivolumab 1Measles-Mumps-Rubella Vaccine 1Hypothermia, Induced 1Heptavalent Pneumococcal Conjugate Vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hepatitis B × PHY 906 × Clear all
NCT04000737 2025-04-13

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

Yiviva Inc.

Phase 2 Completed
62 enrolled
Gastrointestinal

Hepatitis B, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡